Whatever the Clostridium difficile situation in your hospital, Bioquell can tailor a solution to help prevent outbreaks from occurring and reduce the overall incidence of C. difficile infection.
Bioquell has successfully bio-decontaminated over 40,000 rooms at risk of C. difficile contamination worldwide. We have performed over 100 successful outbreak responses, and have many examples of published case studies.
> Explore our C. difficile microbiology area.
Each Clostridium difficile Eradication Program is tailored to an individual hospital's specific needs. Bioquell works closely with hospital infection control teams to integrate Bioquell's hydrogen peroxide vapor (HPV) technology with existing C. difficile remediation protocols or infection control bundles. A typical program consists of elements of Bioquell's core service offerings:
Can Bioquell kill C. difficile spores?
Yes, Bioquell’s HPV is sporicidal. It has been approved by the US EPA as such and has extensive efficacy over spores, including Anthrax. The latest UK guidelines for controlling C. difficile recommend consideration of HPV to provide total disinfection of the environment/equipment in single rooms/isolation wards used to care for patients with C. difficile (UK Department of Health and Health Protection Agency: Clostiridum difficile – how to deal with the problem).
What evidence is there that Bioquell can reduce endemic rates?
The hospital-wide introduction of Bioquell HPV was associated with a reduction in the incidence of C. difficile infection in a study published in 2008 from a US hospital (Boyce JM, Havill NL, Otter JA et al. Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008; 29: 723-729). Two papers presented at conferences since then by US hospitals report significant reductions in C. difficile and the risk of VRE acquisition (Passaretti CL, Otter JA, Lipsett P et al., Adherence to Hydrogen Peroxide Vapor (HPV) decontamination reduces VRE acquisition in high-risk units. 48 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). Washington DC, USA, 2008. Abstract K4124b; Manian FA, Griesenauer S, Senkel D. Impact of an intensive terminal cleaning and disinfection (C/D) protocol involving selected hospital rooms on endemic nosocomial infection (NI) rates of common pathogens at a tertiary care medical center. 5th Decennial Meeting of the Society for Healthcare Epidemiology of America (SHEA), Atlanta, GA, USA. Abstract LB6). A recent letter from a UK hospital reported that a reduction in the incidence of C. difficile was associated with the implementation of Bioquell HPV (Cooper T, O’Leary M, Yezli S, Otter JA. The impact of environmental decontamination using hydrogen peroxide vapour on the incidence of Clostridium difficile infection in one hospital trust. J Hosp Infect accepted). Other research investigating the impact of Bioquell on endemic rates of infection is ongoing.
Total pathogen elimination is verified by inactivation of 6-log Geobacillus stearothermophilus biological indicators, the same method used to validate steam sterilizers/autoclaves. Critically, it does not rely on the operator to ensure the distribution and contact time required to eradicate C. difficile spores.
Bioquell provides the only room/area bio-decontamination technology on the market with a proven track record in reducing the incidence of C. difficile infection (CDI) in both endemic and epidemic settings. One US study has shown that the hospital-wide use of Bioquell HPV technology to bio-decontaminate a room used to care for C. difficile patients resulted in a statistically significant 53% reduction in the incidence of CDI and another US study showed a 42% reduction. Furthermore, Bioquell’s technology has been used in UK hospitals to control outbreaks of C. difficile. Several UK hospitals use Bioquell daily for the bio-decontamination of rooms used to care for patients with C. difficile. Reducing C. difficile acquisition rates reduces the direct costs of CDI and provides further benefits in terms of increased patient turnover.